NYTimes Letter to the Editor: Drug Shortages Continue to Vex

  • | by: Peter J. Pitts |
  • 02/10/2015 12:00 AM
by is licensed under

Re “Drug Shortages Continue to Vex Doctors” (news article, Feb. 11):
 
When it comes to addressing drug shortages, economic factors aren’t just “a contributing factor”; they’re the main factor.
 
Most of America’s drug shortages arise in the generics market, where profitability is fairly low. This market can sustain only a handful of manufacturers, so when supply disruptions occur, there aren’t a lot of additional producers (or in many cases any) in the market to pick up the slack.
 
Drugs that hold relatively stable prices, on the other hand, tend not to experience shortages, according to an October 2011 report by the Department of Health and Human Services. In other words, artificially low prices caused mainly by government programs — ranging from Medicaid to the problematic 340B discount drug program — have caused shortages. Where there’s still a profit, there are rarely shortages.
 
PETER J. PITTS

Washington, Feb. 11, 2014
 
The writer, a former associate commissioner of the Food and Drug Administration, is president of the Center for Medicine in the Public Interest.
Article Photo Credit: by is licensed under
Sign Up for Our Email Newsletter

RECENT NEWS

The coronavirus could help pharma reset its reputation in Washington

The coronavirus could help pharma reset its reputation in Washington

The coronavirus outbreak could be the pharmaceutical industry’s ticket to saving its reputation in Washington....  Read more

The biggest challenge facing the FDA’s new Rare Disease Innovation Hub

The biggest challenge facing the FDA’s new Rare Disease Innovation Hub

Differing philosophies within and outside of government could doom the hub...  Read more

Tort bar’s newest collateral damage: Preterm babies

Tort bar’s newest collateral damage: Preterm babies

Lawsuits allege links between intestinal disease, infant formula and human milk fortifiers...  Read more

DRUGWONKS BLOG